Dermatology

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes.

Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®).

Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.

Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option.

Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™).

Explore a comprehensive overview of pediatric hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This article delves into its epidemiology, pathogenesis, clinical features, associated comorbidities, and treatment challenges. Gain insights into the unique aspects of pediatric HS, including its impact on quality of life and the importance of early diagnosis and management.

Discover the latest insights into managing cutaneous leishmaniasis (CL), including its epidemiology, prevention, diagnosis, and treatment advancements. This article highlights rising global cases, travel-related risks, and evolving clinical strategies to combat this neglected tropical disease.

Update on Cosibelimab-ipdl IV use (Unloxcyt™), Ustekinumab-kfce SC/IV use (Yesintek™), Minocycline hydrochloride capsules (Emrosi™).

Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.

Discover how trifarotene, a fourth-generation retinoid, effectively treats acne and post-inflammatory hyperpigmentation (PIH). Learn about its benefits, clinical evidence, and role in managing acne sequelae.

Update on Ruxolitinib phosphate cream 1.5% (Opzelura®), Roflumilast foam 0.3% (Zoryve®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% fixed-dose topical gel (Cabtreo™), Lebrikizumab-lbkz (Ebglyss™ SC injection), Ustekinumab-srlf (Imuldosa™ SC/IV injection), Ustekinumab-aauz (Otulfi™ SC/IV injection), Ustekinumab biosimilar (Pyzchiva™ SC/IV injection).

Comprehensive review of methoxyflurane inhaled analgesia in dermatology, discussing efficacy, safety, and applications in outpatient procedures for effective pain management.

Discover advancements in oral isotretinoin formulations, including micronized isotretinoin, improving bioavailability and reducing food dependency for optimal acne treatment outcomes.

Update on Nemolizumab-ilto SC injection (Nemluvio®), Denileukin diftitox-cxdl IV use (Lymphir™), Deuruxolitinib phosphate tablets (Leqselvi™), Roflumilast cream (Zoryve™), Ustekinumab-ttwe SC/IV injectio (Pyzchiva®), Sofpironium gel, 12.45% (Sofdra™), Ustekinumab biosimilar (Steqeyma® SC/IV injection) and Lebrikizumab SC injection (Ebglyss™)

Review of the effectiveness of trifarotene, a novel retinoid, in managing atrophic acne scars, highlighting its targeted action on retinoid acid receptor gamma (RAR-γ) and presenting recent clinical data supporting its use as a valuable adjunct treatment for acne scarring.

Explore the role of hormones in managing adult female acne with insights from Dr. Jennifer Lipson. Understand the pathophysiology, prevalence, and impact of hormonal therapies including oral contraceptives, spironolactone, and new topical treatments like clascoterone cream. Discover effective strategies for targeting hormones to treat this common and challenging condition.

Update on Adalimumab-adbm for SC injection (Cyltezo®), Secukinumab for SC injection (Cosentyx®), Tirbanibulin 1% ointment (Spevigo™), LetibotulinumtoxinA-wlbg IM use (Letybo™), and Bimekizumab SC use (Bimzelx®).

This article reviews the use of intravenous immunoglobulin (IVIG) in dermatology, highlighting its role in treating autoimmune and inflammatory skin diseases. It discusses how IVIG reduces the need for steroids or immunosuppressants and its applications in conditions such as autoimmune bullous dermatoses, dermatomyositis, and Stevens-Johnson syndrome. The article also addresses dosing regimens, potential adverse effects, and the importance of ongoing research to further understand the efficacy and safety of IVIG in dermatologic treatments.

A review of the long-term efficacy and safety of tildrakizumab, a monoclonal antibody targeting the IL-23/IL-17 pathway, in treating moderate-to-severe plaque psoriasis. Evidence from Phase 3 clinical trials and extension studies demonstrates that tildrakizumab is an effective and well-tolerated therapy, significantly improving skin clearance and maintaining a favorable safety profile over several years of use.

Update on Mavorixafor capsules (Xolremdi™), Ustekinumab-aekn SC use (Selarsdi™), Spesolimab-sbzo IV/SC use (Spevigo™), LetibotulinumtoxinA-wlbg IM use (Letybo™), and Bimekizumab SC use (Bimzelx®).

Explore current and emerging therapies for Hidradenitis Suppurativa (HS), a chronic, painful skin condition. This article reviews the challenges of HS treatment and introduces novel approaches including biologics like secukinumab and innovative therapies in clinical trials.

Discover the diverse dermatological manifestations in COVID-19 patients, including chilblain-like lesions, maculopapular rashes, and necrosis, reflecting the virus's complex impacts beyond respiratory symptoms. This review highlights the need for further research into these skin conditions' pathogenesis and treatment.

Update on Adalimumab-ryvk for SC injection (Simlandi®), B-Raf inhibitor gel (LUT014), Lifileucel tumorinfiltrating lymphocyte (TIL) suspension for IV use (Amtagvi™), Berdazimer topical gel, 10.3% (Zelsuvmi™), Artificial intelligencepowered skin cancer diagnostic tool (DermaSensor™), Smallpox vaccine (ACAM2000®), Oral brincidofovir (Tembexa®), Ritlecitinib tosylate capsules (Litfulo™), Ustekinumab biosimilar (Jamteki™).

Explore the groundbreaking role of Spesolimab, a novel interleukin-36 inhibitor, in treating Generalized Pustular Psoriasis flares in adults. This article presents key findings from phase 1 and 2 clinical trials, emphasizing Spesolimab's effectiveness and safety.

Explore the efficacy of 1726 nm lasers, specifically AviClear and Accure systems, in treating moderate to severe acne vulgaris, offering a safe and effective alternative to systemic therapies.

Update on Roflumilast foam, 0.3% (Zoryve®), Birch triterpenes gel (Filsuvez®), Rapamycin anhydrous gel, 3.9% (Qtorin™), Bimekizumab-bkzx for SC use (Bimzelx®), Secukinumab for SC use (Cosentyx®), and Ustekinumab-auub for SC/IV use (Wezlana™).

Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

Update on Bimekizumab-bkzx for SC injection (Bimzelx®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%fixed-dose topical gel (Cabtreo™), Roflumilast cream 0.3% (Zoryve®), Nivolumab for IV use (Opdivo®), Secukinumab for IV use (Cosentyx®)

Targeting PDE4 with the selective inhibitor roflumilast, specifically through topical cream at a concentration of 0.3%, has proven to be an effective and well-tolerated strategy for treating plaque psoriasis.

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Update on Cantharidin topical solution 0.7% (Ycanth™), Ritlecitinib capsules (Litfulo™), Clascoterone cream 1% (Winlevi®), and Isotretinoin capsules micronized formulation (Absorica LD®).

DAXI's innovative biochemical composition, replacing HSA with the peptide RTP004, enhances its efficacy, safety, and duration, potentially using less core neurotoxin, positioning it as a groundbreaking botulinum toxin A (BoNTA) for dynamic facial lines treatment.

Dermatologists should be proactive in recommending RZV to all patients over age 50 years, particularly those with a family history of zoster and diseases with altered immune function. Adult patients who are immunocompromised because of their diseases or treatment (e.g., systemic steroids, JAK inhibitors, combination biologic/conventional disease-modifying antirheumatics), should also be encouraged.

Update on Roflumilast cream 0.3% (Zoryve™), Adalimumab-aaty SC use (Yuflyma®), Beremagene geperpavec-svdt topical gene therapy (Vyjuvek™), Molecular imaging device (Orlucent®), Tirbanibulin ointment 1% w/w (Onakta™), Pegunigalsidase alfaiwxj for IV use (Elfabrio®), Autologous cell harvesting device (Recell® System), and Odevixibat capsules/pellets (Bylvay®).

Oral JAK inhibitors are now the first-line treatment for advanced alopecia areata, surpassing topical JAK inhibitors. Baricitinib's FDA approval in 2022 was a significant milestone. More JAK inhibitors are being studied, and additional medications may gain approval soon. JAK inhibitors show promise for alopecia areata with a generally good safety profile, but long-term data is lacking.

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.

Update on Targeted alkali thermolysis (TAT) technology (Brella™ 3-miniute SweatControl Patch™), Retifanlimab-dlwr for IV infusion (Zynyz™), Spesolimab IV for IV infusion (Spevigo®) and CRISPR-based therapy (NTLA-2002).

The proper and suitable application of antibiotics is crucial in maintaining their effectiveness amidst growing antibiotic resistance. Nevertheless, it is essential for prescribing practitioners to have a heightened understanding of resistance causes and strategies to counteract them.